Rodman & Renshaw Initiates Coverage On Leap Therapeutics with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Leap Therapeutics (NASDAQ:LPTX) with a Buy rating and set a price target of $8.
June 28, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Leap Therapeutics with a Buy rating and set a price target of $8.
The initiation of coverage with a Buy rating and a price target of $8 by Rodman & Renshaw is likely to positively impact Leap Therapeutics' stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100